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Streptococcus equi subspecies equi (S. equi) is a clonal, equine host-adapted 
pathogen of global importance that causes a highly contagious suppurative 
lymphodendopathy of the head and neck, more commonly known as Strangles. 
The disease is highly prevalent, can be severe and spread easily by visibly 
infected animals or by carrier animals that show no clinical signs of disease. 
Antibiotic treatment is usually ineffective. However, the majority of horses 
develop immunity to re-infection, suggesting that vaccination should be a 
feasible way to prevent the infection. Live attenuated vaccine strains of S. equi 
are available but adverse reactions have been reported and they suffer from a 
short duration of immunity. Thus, a safe and effective vaccine against S. equi is 
highly desirable. In this report, Welsh mountain ponies vaccinated with a 
combination of seven recombinant S. equi proteins, were significantly protected 
from experimental infection by S. equi, resembling the spontaneous disease. The 
protective antigens consisted of five surface localized proteins and two IgG 
endopeptidases. The results from a second vaccination trial indicate that the 
endopeptidases were important for good protection. The similarity of S. equi to 
other pyogenic streptococci suggests that our findings have broader implications 
for the prevention of streptococcal infections.  
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Strangles is characterized by abscessation of the lymph nodes of the head and neck 
and is of significant welfare and economic importance. The development of effective 
preventative vaccines has been slow. A non-encapsulated strain of S. equi (Pinnacle 
IN™) has been used as a nasal vaccine against strangles, but has not been licensed for 
sale in Europe due to safety concerns. A second live attenuated vaccine was marketed 
in Europe 1 (Equilis StrepE), but was withdrawn in 2007. Safety concerns have also 
been raised over the use of Equilis StrepE 2,3. A safe and effective vaccine is thus 
highly desired. 
 
S. equi evolved from an ancestral strain of S. equi subsp. zooepidemicus (S. 
zooepidemicus). The population of the S. zooepidemicus group is extremely diverse 
and consists of at least 219 sequence types, whereas isolates of S. equi are either ST-
179 or a single locus variant, ST-151 that are characteristic of S. equi isolates from the 
USA, Canada, Australia and Europe 4 (http://pubmlst.org/szooepidemicus/). The 
limited genetic diversity of S. equi suggests that an effective vaccine could confer 
broad protection to horses throughout the world. 
 
Access to the genome sequence data of bacterial pathogens permitting the 
identification of surface exposed and secreted proteins has long been anticipated to 
revolutionize vaccine design, referred to as reverse vaccinology 5,6. However, few 
vaccines have been taken beyond studies in mouse model systems and shown to 
confer protection against challenge infection in the natural host.  
 
We have demonstrated previously that vaccination of Welsh mountain ponies with 
EAG 7,8, SclC 9 and CNE 10 (Trivacc) conferred partial protection against challenge 
by S. equi 11. The amount of nasal discharge, the number of bacteria recovered from 
nasal washes and the occurrence of abscess material (empyema) in the guttural pouch, 
following rupture of abscesses formed in the retropharyngeal lymph nodes, differed 
significantly between the vaccinated group and a non-vaccinated control group. 
However, clinical scoring and mean rectal temperatures were not significantly 
different. This experiment thus showed that parameters of importance for spreading 
disease between horses were significantly reduced, but that the level of protection in 
individual horses was limited 11.  
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We report here the use of a combination of seven antigens in a vaccine, Septavacc, to 
prevent S. equi infection. Five of the antigens in the Septavacc composition are 
predicted to be localized on the surface of S. equi (EAG 7,8, CNE 10, SclC 12, 
SEQ0256 and SEQ040213) through sortase-mediated attachment to the peptidoglycan 
cell wall. EAG binds to albumin, -2 macroglobulin (A2M) and IgG 8,14. CNE binds 
to collagen 10, and is located within the FimI pilus locus of S. equi and S. 
zooepidemicus 13,15. SclC is a member of a collagen-like protein family, which in S. 
equi consists of seven members, each with a unique N-terminal domain of unknown 
function 12. The proteins encoded by SEQ0256 and SEQ0402 contain features typical 
of cell surface anchored proteins and an N-terminal non-repetitive domain. The N-
terminal domains were used in this study, the functions of which are unknown. 
Neither of them show homology to any characterized protein. The two additional 
antigens in Septavacc, IdeE and IdeE2 are IgG endopeptidases where IdeE2 has 
greater activity towards horse IgG. Both IdeE and IdeE2 are predicted to be secreted 
16,17 and IdeE has an antiphagocytic activity by binding directly to neutrophils 17. 
These antigens were selected from a larger antigen pool based on the level of 
protection conferred in an experimental mouse model of strangles. Mice were 
immunized with recombinant antigens either individually, or in combination, 
experimentally infected with S. equi and the effectiveness of each antigen ranked 
(Supplementary Table 1).  
 
Seven Welsh mountain ponies were vaccinated with Septavacc and seven were given 
adjuvant only as control via both the subcutaneous and intranasal routes, followed by 
experimental infection with 1 x 108 colony forming units (cfu) of S. equi strain 4047. 
Serum samples and nasal washes were analyzed by ELISA to quantify the antibody 
responses against all antigens (Supplementary Figures 1 a and b). All ponies 
responded well and it was noted that responses in nasal washes had low correlation 
with responses in sera (R2 from 0.01 to 0.28), implying the generation of independent 
immune responses in mucosa and sera, possibly as a result of the two routes of 
immunization employed. 
 
The swelling and abscessation of submandibular lymph nodes is a typical clinical sign 
of infection by S. equi. Figure 1 shows that the mean lymph node scores differed 
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between the groups and that the number of days where an individual pony’s score 
exceeded 2 was significantly different (p= 0.0013) with two vaccinated ponies and 
four control ponies exceeding this level. 
 
The normal rectal temperature of Welsh mountain ponies is 37-38oC and a pony with 
a rectal temperature of 39oC or higher is considered pyrexic. All ponies in the control 
group became pyrexic at some stage during challenge compared to only one pony in 
the vaccinated group. The accumulated number of days that individual ponies in the 
vaccinated or control groups were pyrexic was 5 and 30 days, respectively (p=0.0001) 
(Figure 2). 
 
Infection by S. equi leads to an increase in blood fibrinogen and neutrophil levels. As 
shown in Figure 3 a and b, fibrinogen and neutrophil levels of vaccinated ponies 
remained normal, whereas the non-vaccinated group had significantly higher mean 
values.  
 
To minimize suffering and in accordance with our strict ethical and welfare code, 
ponies were euthanized as soon as clinical signs of S. equi infection became apparent. 
All of the control ponies were euthanized between 8 to 12 days post challenge. 
Vaccinated horses, however, had reduced clinical signs and all ponies reached the end 
of the study, 21 days post challenge. Following euthanasia, all of the ponies were 
subject to post mortem examination to quantify the level of pathology observed using 
a scoring system as described in Methods.  
 
In a separate study, seven ponies were immunized with a Pentavacc formulation, 
containing the same antigens as in Septavacc with the exception of IdeE and IdeE2, 
and then challenged S. equi. Although the Pentavacc ponies differed from the 
corresponding control group in terms of elevated temperature, fibrinogen levels and 
nasal discharge, this was not statistically significant. One pony was fully protected.  
 
Figure 4 summarizes the individual post mortem scores of ponies vaccinated with 
Trivacc, Pentavacc and Septavacc, which contain three, five and seven antigens 
respectively. Increasing the number of antigens comprising each vaccine reduced the 
post mortem score. However, the large improvement in efficacy between Pentavacc 
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and Septavacc (p=0.036 for post mortem scoring), suggests that inclusion of one or 
both of the endopeptidases IdeE and IdeE2 is important for protection in the natural 
host. Only one of the ponies vaccinated with Septavacc had lymph node abscesses, 
compared with abscesses in all seven non-vaccinated ponies. To confirm these gross 
pathological findings, samples from ponies vaccinated with Septavacc were examined 
histopathologically and scored using a system as described in Methods. Again, 
significant differences were seen between the Septavacc and control groups (p=0.006) 
(Supplementary Figure 2). Histopathological examination of the left and right 
retropharyngeal and submandibular lymph nodes identified 19 lymph node abscesses 
in the control ponies and 3 lymph node abscesses in a single pony in the Septavacc 
group (p=0.00001). Seventy-eight and 10 % of all lymph nodes were positive for S. 
equi in the control and vaccine groups respectively (p=0.004).  
 
Taking all of the results together, vaccination with Septavacc resulted in 85% 
protection from disease, with only one vaccinated pony out of seven being infected. 
 
In a study by Timoney et al, 18 two combinations of recombinant extracellular 
proteins derived from S. equi (SzPSe, CNE, Se51.9, Se44.2 and Se46.8 or SeM, 
Se44.2, Se75.3, Se42.0, Se110.0 and Se18.9) were tested as vaccines against 
strangles. However, neither combination protected horses from infection by S. equi 18. 
Two of these proteins CNE and IdeE2 (Se44.2) are included in the Septavacc vaccine, 
suggesting that the additional components of Septavacc are important in generating a 
protective immune response. It was also suggested that an effective strangles vaccine 
should result in immune-mediated tonsillar clearance since tonsillar adherence is a 
crucial early step in the pathogenesis of strangles 18,19. Thus, the route of 
immunization and choice of adjuvant, which differ between these studies, might be of 
utmost importance, an issue to be further addressed in our future studies. It should be 
noted that mice immunized by the intranasal route are far better protected than those 
immunized subcutaneously (data not shown). 
 
S. equi shares >80% sequence identity with Streptococcus pyogenes 13 and several 
components utilized in our studies have similarities to S. pyogenes antigens, either by 
homology or function. The S. pyogenes gene encoding the collagen binding protein 
Cpa is located in the variable FCT region (fibronectin- and collagen-binding T-
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antigen) and is part of a pilus-like structure 20. Similarly, cne is located in a pilus 
locus (FimI) that includes genes encoding SrtC.1 and a putative backbone pilus 
subunit suggesting that also CNE is attached to a pilus-like structure 13. EAG, like 
GRAB from S. pyogenes, binds the proteinase inhibitor A2M 8,21,22. SclC is one of 
seven collagen-like surface proteins in S. equi, whilst S. pyogenes genomes contain 
two such putative proteins, SclA and SclB 9. The IgG-specific endopeptidases used 
here, IdeE and IdeE2, are similar both in function and amino acid sequence to 
IdeS/Mac/sib35 of S. pyogenes 16,17,23,24. Antibodies against IdeS in convalescent 
patients were able to neutralize its function 25. Interestingly, Cpa (plus other pili 
components), GRAB and Sib35 have been identified as protective antigens in mouse 
models of S. pyogenes infection. The Cpa combination and Sib35 gave good 
protection whereas vaccination with GRAB was only effective against capsule-
deficient mutants of S. pyogenes 26-28. Thus, it is conceivable that vaccination of 
humans with a combination of S. pyogenes antigens similar to the ones used in 
Septavacc, could prove effective against this important human pathogen. 
 
This study is one of only a few demonstrations of protection in a natural host from 
streptococcal infection conferred by a recombinant multi-component subunit vaccine. 
A protective immune response against S. equi infection can be obtained by 
immunization using recombinant antigens and does not necessarily require previous 
infection or a subclinical infection, a strategy taken by vaccines based on attenuated 
live vaccines. No adverse effects were seen in any of the vaccinated horses, 
demonstrating that both the recombinant antigens and the adjuvant were safe. It is 
also clear that the antiphagocytic capsule did not prevent successful vaccination with 
the recombinant proteins used here. The approach taken here is likely to be 
significantly safer than live attenuated strains of S. equi.  
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METHODS 
 
Cloning and production of recombinant antigens. 
Antigens used in the vaccination studies were cloned and expressed in Escherichia 
coli (Supplementary methods). 
 
Mouse model of strangles 
Mice were immunized with recombinant antigens followed by experimental infection 
with S. equi. Infection was assessed by nasal colonization and weight loss 29, 7 
(Supplementary Methods). 
 
Immunization of ponies 
Healthy Welsh Mountain Ponies (n=7) were vaccinated with Septavacc via 
administration of 1 ml subcutaneous (s.c.) injections bilaterally close to the 
retropharyngeal lymph nodes and 2 ml intranasally (i.n.) by spraying into each nostril 
on days 4, 60, and 74. The Septavacc vaccine doses contained 150 g for i.n. and 50 
g for s.c. injections of each antigen (EAG, CNE, SclC, SEQ0256, SEQ0402, IdeE, 
and IdeE2). Abisco 300 (Isconova, Uppsala, Sweden) (500 g per i.n. dose) and 
Abisco 200 (375 g per s.c. dose) were used as adjuvants. Septavacc ponies were 
challenged on day 88. Pentavacc vaccinated ponies (n=7) followed the same 
vaccination protocol as above, but were given an additional booster vaccination on 
day 270 and challenged on day 284. Negative control ponies were given adjuvant 
only, mixed with PBS (n=7). Sera and nasal washes were taken regularly to quantify 
antibody responses by ELISA 11. 
 
Experimental infection of ponies 
Ponies were transferred to a containment unit three days before challenge. Two weeks 
after the final booster immunization, each pony was challenged with S. equi strain 
4047 administered via the spraying of a 2 ml culture containing 5x107 cfu into each 
nostril. Bacteria were grown overnight in Todd Hewitt broth and 10% foetal calf 
serum (THBS) in a 5% carbon dioxide enriched atmosphere at 37oC, diluted 40-fold 
in fresh pre-warmed THBS, further cultivated and harvested at an OD=0.3. This 
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infection dose has been shown to optimize the infection rate, whilst avoiding 
overwhelming the host immune response, as determined in previous studies 11,30. 
 
Clinical evaluation of and sampling from ponies 
Ponies were monitored for the onset of clinical signs of disease over a period of three 
weeks post challenge by daily physical examination, rectal temperature, lymph node 
swelling and nasal discharge scoring. Blood samples were taken for evaluation of 
fibrinogen concentration as described in 11 and neutrophil levels by total white blood 
count performed on Beckman-Coulter ACTdiff analyser with a manual differential 
count to calculate % neutrophils. 
 
The level of swelling of SMLNs was defined as 0 = normal, 1 = slight swelling, 2 = 
moderate swelling, 3 = severe swelling and 4 = abscessated 11. Bilateral swelling of 
submandibular lymph nodes was scored separately 
 
Post mortem examination 
Post mortem examination was performed on all ponies following the onset of clinical 
signs of infection or on reaching the study endpoint at 3 weeks post challenge. The 
severity of disease pathology was quantified according to a scoring system as follows: 
retropharyngeal or submandibular lymph node abscess (evident at gross examination) 
15, retropharyngeal or submandibular lymph node microabscess (evident on 
microscopic examination) 10, empyema of guttural pouch (suppurative exudate in 
lumen on gross or microscopic examination) 5, scarring of guttural pouch (fibrosis of 
wall on gross or microscopic examination) 5, enlarged lymph node (showing non-
specific hyperplastic changes on microscopy) 1, follicular hyperplasia of guttural 
pouch (lymphoid follicles in submucosa on gross or microscopic examination) 1.  
 
Statistics 
Fischer´s exact test was used for comparison of values from arbitrary scoring using a 
cut-off value splitting the group into “low/negative” or “high/positive”. Cut-off values 
were: Nasal colonization in mice 1.5; Lymph node scoring 2; Pyrexia 39oC. Mann 
Whitney test was used for post mortem and histopathology (Supplementary Fig. 2) 
scoring in horses. T-test was used to compare temperatures, fibrinogen and neutrophil 
levels in ponies. 
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Figure legends 
 
 
 
Fig 1 
Lymph node swelling over time. Lymph node swelling was monitored from three 
days pre-challenge (day 85) using an arbitrary scale from 0 to 4. Average values and 
standard error from the mean (SEM) are shown. The insert shows accumulated 
number of days a pony was considered positive, i.e. with a value exceeding 2. p-value 
in insert: **p=0.0013. Non-vaccinated (open symbols) (n=7) and Septavacc 
vaccinated (closed symbols) (n=7). 
 
Fig 2  
Temperature over time. Mean rectal temperature was monitored from three days pre-
challenge (day 85). Average values and SEM are shown. The insert shows 
accumulated number of days a pony was considered pyrexic, i.e. with a temperature 
exceeding 39.0oC. p-value in insert: ***p=0.0001. Non-vaccinated (open symbols) 
(n=7) and Septavacc vaccinated (closed symbols) (n=7). 
 
Fig 3  
Inflammatory markers over time. Neutrophil counts (a) and fibrinogen levels (b) were 
monitored from two days pre-challenge (day 86). Average values and SEM are 
shown. p-values: **p=0.002, ***p=0.0004 in (a), *p=0.024, **p=0.002 in (b). Non-
vaccinated (open symbols) (n=7) and Septavacc vaccinated (closed symbols) (n=7). 
 
Fig 4  
Post mortem score. Ponies were vaccinated with three different antigen combinations, 
(Trivacc, Pentavacc and Septavacc) followed by challenge with S. equi. Post mortem 
scoring was performed using a scoring system described in Methods. Non-vaccinated 
(open symbols) and vaccinated (closed symbols). 
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